IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Fairmount Funds Management LLC

Q2 2023 Holdings

Filed 2023-08-14 | 17 holdings | $709.3M | 13F-HR | View on SEC ↗ · Holdings Table ↗

Sign in to see sub-manager breakdown

IssuerClassCUSIPValue ↓Shares% Portfolio
Axsome Therapeutics Inc(AXSM)COM05464T104$168.5M2,344,98023.8%
Nuvalent Inc(NUVL)COM670703107$121.6M2,884,49217.1%
Immunogen Inc(IMGNEUR)COM45253H101$113.8M6,029,59216.0%
Enliven Therapeutics Inc(ELVN)COM29337E102$43.4M2,124,6256.1%
Cogent Biosciences Inc(COGT)COM19240Q201$42.1M3,558,9755.9%
Merus N VCOMN5749R100$39.0M1,482,4055.5%
Viridian Therapeutics Inc(VRDN)COM92790C104$32.6M1,369,6234.6%
Argenx SE(ARGX)SPONSORED ADR04016X101$28.7M73,5264.0%
Tyra Biosciences Inc(TYRA)COM90240B106$24.1M1,416,9983.4%
Terns Pharmaceuticals Inc(TERN)COM880881107$17.9M2,040,0002.5%
Astria Therapeutics Inc(CATBUSD)COM04635X102$15.8M1,901,3972.2%
Kodiak Sciences Inc(KOD)COM50015M109$13.7M1,985,2451.9%
DBV Technologies SASPONSORED ADR23306J101$13.4M7,064,9641.9%
Trevi Therapeutics Inc(TRVI)COM89532M101$12.4M5,190,3601.7%
Kiniksa Pharmaceuticals LTDCOM CL AG5269C101$9.9M704,4591.4%
Verona Pharma PLC(VRNA)SPONSORED ADS925050106$8.1M381,9391.1%
Aeglea Biotherapeutics Inc(AGLEUSD)COM00773J103$4.3M9,460,5400.6%